These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 25052698)

  • 1. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
    Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
    Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
    Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
    Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
    Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
    Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
    Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
    Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.
    Vigliotti ML; Dell'Olio M; La Sala A; Romano G; Tartarone A; Mele G; Musto C; Carella AM; Di Renzo N
    Hematol J; 2004; 5(5):453-5. PubMed ID: 15448676
    [No Abstract]   [Full Text] [Related]  

  • 15. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
    Moreton P; Morgan GJ; Gilson D; Smith GM; McVerry BA; Davies JM; Mackie MJ; Bolam S; Jalihal SS; Howard MR; Parapia LA; Williams AT; Child JA;
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):324-8. PubMed ID: 14704830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.
    Illerhaus G; Marks R; Müller F; Ihorst G; Feuerhake F; Deckert M; Ostertag C; Finke J
    Ann Oncol; 2009 Feb; 20(2):319-25. PubMed ID: 18953065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)].
    Sano F; Koike M; Nakamura K; Wakayama T; Kunika N; Kubomatsu Y; Katoh M; Chisa M; Hasegawa S; Takahashi M
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2389-93. PubMed ID: 1463345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
    Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
    Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.